LB Pharmaceuticals Appoints Minako Pazdera, J.D., Ph.D. as General Counsel

Company Overview - LB Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases [5] - The company is advancing its lead product candidate, LB-102, which is a Phase 3-ready oral small molecule and a methylated derivative of amisulpride [4] Leadership Appointment - Dr. Minako Pazdera has been appointed as General Counsel, bringing over 25 years of experience in corporate governance, intellectual property, strategic corporate transactions, and compliance [2][3] - Dr. Pazdera previously served as General Counsel and Corporate Secretary at Kardigan and Carmot Therapeutics, where she led the legal function during a dual track IPO/strategic transaction process that resulted in Carmot's acquisition by Roche for up to $3.1 billion in 2024 [3] Product Development - LB-102 has shown positive data from a Phase 2 trial in patients with acute schizophrenia, demonstrating statistically significant benefits versus placebo and a potentially class-leading safety profile among D2 antagonists and partial agonists [4] - The company plans to initiate a Phase 3 clinical trial for acute schizophrenia and a Phase 2 clinical trial for bipolar depression, with potential expansion opportunities into major depressive disorder, Alzheimer's disease psychosis, and other conditions [4] Strategic Vision - The company aims to build a fully integrated CNS-focused company and is poised to provide new treatment options for patients with complex neuropsychiatric disorders [4][3] - LB-102 is positioned to potentially become the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States, offering an attractive alternative to existing therapies [5]